Browse by Series:

CDK4/6 Inhibitors for HR+ Breast Cancer; Emergence of Ribociclib

Adam Brufsky,MD
Published: Tuesday, Mar 14, 2017

Slider Left
Slider Right
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x